Advanced Imaging and Image Analysis Services
Digital Pathology, Machine Learning and 3D Cell Culture Models
Date: October 25, 2018
Time: 9am PDT/12pm EDT/4pm UTC
Format: 30 minutes with 10 minutes live Q&A
3D cell culture models can be powerful, predictive tools for drug discovery and development. Recent advances in image analysis can extract richer, more detailed information from these models.
Attend this webinar to learn about:
- The use of 3D cell culture models (eg. organoids, spheroids, microtissues) in drug discovery
- Application of 3D tissue imaging for studying complex phenomena such as angiogenesis
- How digital pathology and machine learning can be used to extract quantitative data from tissues
Join imaging expert Dr. Michael Johnson from Visikol, Inc.
Three major opportunities for improvement in early-stage in vitro and animal model studies are to improve the predictive capability of in vitro models themselves, the extraction of more complete data from cell cultures and animal models, and to shift from qualitative histological evaluation to a quantitative digital pathology approach.
Through this webinar, Visikol will focus its discussion on the use of 3D cell culture models, the application of 3D tissue imaging for studying complex phenomena such as angiogenesis and how digital pathology and machine learning can be used to extract quantitative data from tissues.
Several areas of ongoing research being pursued at Visikol will be discussed.
- In the high-throughput in vitro space, Visikol has demonstrated the improved utility of 3D cell culture models for several application through showing differential expression of important drug targets in 2D versus 3D and reported a correspondingly differential response to treatment with targeted therapeutics.
- Several considerations for successful development and implementation of 3D cell culture models in similar drug screening campaigns will be discussed with a special emphasis on how data quality can be improved via 3D cell culture tissue clearing and 3D analysis.
- In the in vivo space, Visikol will describe how it is using 3D tissue imaging to run screening campaigns for complex morphological features such as vasculature associated with angiogenesis.
- Lastly, Visikol will detail its recent partnership with Enzyvant Therapeutics and how it is using digital pathology combined with machine learning to extract thousands of insights from individual slides for quantitative analysis.
Who should attend:
- Drug discovery scientists
- Researchers performing immunolabeling
- Computer scientists
About Our Speaker
Michael Johnson, PhD is a 2017 Forbes 30 Under 30 honoree and the CEO and Co-Founder of Visikol Inc., which is a bio-imaging company that spun out of Rutgers University in 2016 and that Michael founded along with his fellow PhD candidate Thomas Villani and colleague Nick Crider. Michael’s research background has focused on a wide range of projects from remote sensing research with NASA to building light sheet microscopes and producing biofuels. Prior to launching Visikol, Michael worked at Johnson & Johnson and several other biotech-based entrepreneurial pursuits. He is passionate about translating cutting-edge research into life-changing commercial technologies. It was through the interdisciplinary component of his NSF PhD Fellowship that Michael met Thomas Villani in 2014 and began working on developing the Visikol technology for animal tissues. Since 2014, Michael, Thomas and Nick have developed the Visikol technology into several high-value imaging platforms and are working to disrupt the bio-imaging paradigm. At Visikol Inc., Michael is responsible for the overall strategy of the company as well as the commercialization of Visikol technologies.
October 25, 2018 | 9am PDT/12pm EDT/4pm UTC
Michael Johnson, PhD, CEO & Co-Founder, Visikol Inc.